ACAD: Q3 revenue rose 22% as both brands grew; rem​​lifanserin advances into Phase 3

What happened

Acadia Pharmaceuticals reported third-quarter revenue of $342.3 million, up 22% year over year, led by growth in DAYBUE and NUPLAZID. It updated its fiscal-year revenue guidance and said remlifanserin would continue into Phase 3 development, although the drug narrowly missed Phase 2’s primary endpoint.

Confirmed

Global impact / market context

Higher sales from both brands can increase revenue and help fund drug development, while the updated outlook may change investors’ expectations for future sales. Continuing remlifanserin into Phase 3 keeps development costs in play despite the missed Phase 2 goal, leaving its eventual commercial value uncertain.

Analyst inference

The reported growth is an operating signal, but the summary gives no updated guidance figures or brand-level sales, limiting comparison with prior expectations. Rem​​lifanserin’s Phase 2 result is mixed: it missed the main study goal, yet the company is proceeding with a larger next-stage trial.

Analyst inference

What to watch

1. Look for the actual updated revenue guidance and how it compares with the previous outlook; the summary confirms a change but provides no figures. Confirmed
2. Watch for details on remlifanserin’s Phase 3 trial design, timing, and cost, which will clarify the development commitment after the Phase 2 miss. Analyst inference
3. Track whether DAYBUE and NUPLAZID sustain sales growth, since continued brand revenue could support company income and spending on drug development. Analyst inference

Evidence

• Original source link unavailable